These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 1346818)

  • 21. South India immunoprophylaxis trial against leprosy: relevance of findings in the context of leprosy trends.
    Gupte MD
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S10-3. PubMed ID: 11757173
    [No Abstract]   [Full Text] [Related]  

  • 22. Venezuela results and after.
    Gupte MD
    Indian J Lepr; 1992; 64(4):451-9. PubMed ID: 1308519
    [No Abstract]   [Full Text] [Related]  

  • 23. Armadillos (Dasypus novemcinctus) as a model to test antileprosy vaccines; a preliminary report.
    Job CK; Sanchez RM; Hunt R; Truman RW; Hastings RC
    Int J Lepr Other Mycobact Dis; 1993 Sep; 61(3):394-7. PubMed ID: 8228437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal vaccination studies with Mycobacterium leprae.
    Shepard CC
    Int J Lepr Other Mycobact Dis; 1983 Dec; 51(4):519-23. PubMed ID: 6368416
    [No Abstract]   [Full Text] [Related]  

  • 25. BCG and Adverse Events in the Context of Leprosy.
    Richardus R; van Hooij A; van den Eeden SJF; Wilson L; Alam K; Richardus JH; Geluk A
    Front Immunol; 2018; 9():629. PubMed ID: 29670618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
    Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts.
    Convit J; Aranzazu N; Ulrich M; Pinardi ME; Reyes O; Alvarado J
    Int J Lepr Other Mycobact Dis; 1982 Dec; 50(4):415-24. PubMed ID: 6763002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationales for vaccines against leprosy.
    Bloom BR
    Int J Lepr Other Mycobact Dis; 1983 Dec; 51(4):505-9. PubMed ID: 6368414
    [No Abstract]   [Full Text] [Related]  

  • 29. The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study).
    Richardus RA; Alam K; Pahan D; Feenstra SG; Geluk A; Richardus JH
    BMC Infect Dis; 2013 Oct; 13():456. PubMed ID: 24088534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis.
    Chaudhury S; Hazra SK; Saha B; Mazumder B; Biswas PC; Chattopadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):389-94. PubMed ID: 7963911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of proliferative response to M. leprae antigens in lepromatous T cells against candidate antileprosy vaccines.
    Mustafa AS
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):257-67. PubMed ID: 8862259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Convit vaccine (BCG + Mycobacterium leprae) afford protection against biochemical changes in renal brush border membrane in experimental leprosy?
    Kohli M; Ganguly NK; Kaur S; Chugh KS; Sharma VK; Bhushnurmath SR
    Lepr Rev; 1991 Sep; 62(3):269-75. PubMed ID: 1795585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Under-explored experimental topics related to integral mycobacterial vaccines for leprosy.
    Gormus BJ; Meyers WM
    Expert Rev Vaccines; 2003 Dec; 2(6):791-804. PubMed ID: 14711362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycobacterium bovis BCG but not Mycobacterium leprae induces TNF-alpha secretion in human monocytic THP-1 cells.
    Oliveira MM; Charlab R; Pessolani MC
    Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):973-8. PubMed ID: 11685264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study to determine acceptability and ability of heat-killed Mycobacterium leprae plus BCG (HKML+BCG) vaccine to induce skin test conversion.
    Chen ZL; Tang QG; Wang ZM; Chen J
    Lepr Rev; 1993 Jun; 64(2):117-27. PubMed ID: 8341114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG.
    Convit J; Aranzazu N; Pinardi M; Ulrich M
    Clin Exp Immunol; 1979 May; 36(2):214-20. PubMed ID: 383331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine consisting of killed Mycobacterium leprae.
    Gill HK; Mustafa AS; Godal T
    Bull World Health Organ; 1986; 64(1):121-6. PubMed ID: 3524883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long lasting BCG protection against leprosy.
    Rodrigues LC; Kerr-Pontes LR; Frietas MV; Barreto ML
    Vaccine; 2007 Sep; 25(39-40):6842-4. PubMed ID: 17728023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh.
    Richardus RA; Butlin CR; Alam K; Kundu K; Geluk A; Richardus JH
    Vaccine; 2015 Mar; 33(13):1562-7. PubMed ID: 25701674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of antileprosy vaccines].
    Kalianina OV; Iushchenko AA
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (2):93-100. PubMed ID: 15881952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.